Neurotech Vital Compact Versus Itouch Sure Pelvic Floor Exerciser US

NCT ID: NCT02423005

Last Updated: 2018-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2017-04-30

Brief Summary

A prospective, randomised, controlled, single-blind, multi-site clinical study employing Neuromuscular Electrical Stimulation (NMES) to stimulate the pelvic floor muscles of women suffering from stress urinary incontinence.

Approximately one-hundred and eighty (180) female patients diagnosed with stress urinary incontinence will be enrolled in this study. All patients who are considered eligible to participate in the clinical study and give consent will be randomised to complete either a 12-week treatment programme with the Neurotech Vital Compact device or a 12-week treatment programme with the itouch Sure Pelvic Floor Exerciser. The 12-week treatment programme will be completed by the subjects at home with treatment with the device in accordance with the device Instructions for Use.

Detailed Description

This is a prospective, randomised, controlled, single-blind, multi-site clinical study to be conducted in the United States of America (USA) employing Neuromuscular Electrical Stimulation (NMES) to stimulate the pelvic floor muscles of women suffering from stress urinary incontinence.

Approximately one-hundred and eighty (180) female patients diagnosed with stress urinary incontinence will be enrolled in this study. All patients who are considered eligible to participate in the clinical study and give consent will be randomised to complete either a 12-week treatment programme with the Neurotech Vital Compact device or a 12-week treatment programme with the itouch Sure Pelvic Floor Exerciser. The 12-week treatment programme will be completed by the subjects at home with treatment with the device in accordance with the device Instructions for Use.

Subjects included in the clinical study will be evaluated at screening, on enrolment into the study (baseline) and during the 12-week treatment programme at 4 and 12 weeks. A telephone call will be made at 1 week to check on the patient's progress. In addition, subjects will be evaluated at 26 week following their commencement of the treatment.

Conditions

Stress Urinary Incontinence

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Neurotech Vital Compact

The Neurotech Vital Compact will be used by subjects with Stress Urinary Incontinence 5 days per week for 30 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.

Group Type: EXPERIMENTAL

Neurotech Vital Compact

Intervention Type: DEVICE

Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.

itouch Sure Pelvic Floor Exerciser

The itouch Sure Pelvic Floor Exerciser will be used by subjects with Stress Urinary Incontinence 7 days per week for 20 minutes per session for 12 weeks followed by 14 weeks of Kegel exercises.

Group Type: ACTIVE_COMPARATOR

itouch Sure Pelvic Floor Exerciser

Intervention Type: DEVICE

Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.

Interventions

Neurotech Vital Compact

Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.

Intervention Type: DEVICE

itouch Sure Pelvic Floor Exerciser

Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.

Intervention Type: DEVICE

Other Intervention Names

EmbaGYN

Eligibility Criteria

Inclusion Criteria

1. Subjects who are female and at least 18 years of age, and not more than 65 years of age.

2. Subjects who have signed the informed consent form prior to any study related activity.

3. Subjects who have previously tried and failed to improve their condition using Kegel exercises.

4. Subjects who have been clinically diagnosed with stress urinary incontinence and demonstrate a greater than or equal to 3g urine leakage and a less than or equal to 90g urine leakage (>3g and < 90g) following a bladder-filling protocol and then a standardised stress test (provocative pad weight test) at the baseline assessment.

5. Subjects who score 9 or less (<9) out of 18 for the Urge Incontinence Questions and are confirmed as having predominant stress urinary incontinence on the Medical, Epidemiologic and Social Aspects of Aging Urinary Incontinence (MESA) Questionnaire completed at the screening assessment.

6. Subjects with a Body Mass Index of ≤ 35 kg/m2.

7. Subjects of child-bearing potential who are using a highly effective contraceptive method (established use of oral, injected, implanted hormonal method of contraception or barrier method of contraception with spermicide).

8. Subjects who are willing not to seek any other treatment for stress incontinence during the study period.

9. Subjects who are able to give voluntary, written informed consent to participate in this study and from whom consent has been obtained.

10. Subjects who are able to understand this study and are willing to complete all the study assessments.

Exclusion Criteria

1. Subjects who have an existing medical condition that would compromise their participation in the study, e.g. reduced sensory perception in the contact area of the stimulation electrodes; scars or vaginal tissue wounds, lesions or inflamed/infected areas in the contact area of the stimulation electrodes; vaginal bleeding between menstrual periods; uncontrolled diabetes.

2. Subjects who have a physical condition that would make them unable to perform the study procedures, e.g. pelvic or hip surgery within the past 6 weeks.

3. Subjects who have been diagnosed with Chronic Obstructive Pulmonary Disease (COPD).

4. Subjects with a history of an underlying neurological condition, e.g. Multiple Sclerosis, Parkinson's disease, epilepsy.

5. Subjects with any bladder abnormality that would affect the urinary flow through the lower urinary tract including signs or symptoms of an active urinary tract infection, abnormal bladder capacity (e.g., >300 cc), post void residual volume >200 cc, spastic bladder, vesico-ureteral reflux or bladder stones.

6. Subjects with a blood clotting disorder or who are taking anti-coagulant medications.

7. Subjects who have previously had any uro-gynaecological related surgery that would affect the pelvic floor muscles or urinary flow through the urethra (excluding hysterectomy).

8. Subjects who have previously had pelvic floor radiation.

9. Subjects who have previously been treated for stress incontinence with injectable bulking agents and/or vaginal probes within the past 6 months.

10. Subjects with a clinical diagnosis of prolapse greater than Stage 2.

11. Subjects who are pregnant or could be pregnant.

12. Subjects who are less than 6 months post-partum or who are lactating.

13. Subjects who have any conductive intra-uterine devices or metal implants in the pelvic area, including hip and lumbar spine.

14. Subjects with pelvic pain or fibromyalgia or paravaginal defect.

15. Subjects with an active implanted medical device (i.e. pacemaker, insulin pump etc.) or conditions that may be adversely affected by electrical stimulation (e.g. cardiac arrhythmias).

16. Subjects with a current or active history of pelvic cancer and/or subjects with a life expectancy of less than 12 months.

17. Subjects who are currently involved in any injury litigation claims.

18. Subjects who have participated in a clinical study in the last 3 months or any previous clinical study with Bio-Medical Research Ltd.

19. Subjects who have been committed to an institution by virtue of an order issued either by the courts or by an authority.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Bio-Medical Research, Ltd.

INDUSTRY

Sponsor Role: collaborator

Atlantic Therapeutics

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Conor Minogue, PhD

Role: STUDY_DIRECTOR

Bio-Medical Research, Ltd.

Locations

Maricopa Integrated Health Systems

Phoenix, Arizona, United States

University of California Irvine Medical Center

Orange, California, United States

Hartford Hospital

Hartford, Connecticut, United States

Altus Research

Lake Worth, Florida, United States

University of South Florida Medical Center

Tampa, Florida, United States

Boston Clinical Trials

Boston, Massachusetts, United States

AccuMed Research Associates

Garden City, New York, United States

Lyndhurst Gynecological Associates

Winston-Salem, North Carolina, United States

Temple University

Philadelphia, Pennsylvania, United States

Medical University of South Carolina

Charleston, South Carolina, United States

The Jackson Clinic

Jackson, Tennessee, United States

Renaissance Health & Surgical Associates

South Pittsburg, Tennessee, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Informed Consent Form

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

BMR-13-1001

Identifier Type: -

Identifier Source: org_study_id